EXAI Stock Overview
An artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Exscientia plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.53 |
| 52 Week High | US$7.91 |
| 52 Week Low | US$3.80 |
| Beta | 0.85 |
| 11 Month Change | 7.59% |
| 3 Month Change | 11.72% |
| 1 Year Change | -12.50% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.59% |
Recent News & Updates
Recent updates
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
Aug 08Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation
Jul 17
Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09Shareholder Returns
| EXAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.6% | 3.5% | 3.1% |
| 1Y | -12.5% | 14.9% | 25.4% |
Return vs Industry: EXAI underperformed the US Biotechs industry which returned 15.7% over the past year.
Return vs Market: EXAI underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| EXAI volatility | |
|---|---|
| EXAI Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EXAI has not had significant price volatility in the past 3 months.
Volatility Over Time: EXAI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 483 | Dave Hallett | www.exscientia.ai |
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
Exscientia plc Fundamentals Summary
| EXAI fundamental statistics | |
|---|---|
| Market cap | US$709.61m |
| Earnings (TTM) | -US$168.90m |
| Revenue (TTM) | US$27.40m |
26.1x
P/S Ratio-4.2x
P/E RatioIs EXAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXAI income statement (TTM) | |
|---|---|
| Revenue | UK£21.02m |
| Cost of Revenue | UK£27.84m |
| Gross Profit | -UK£6.82m |
| Other Expenses | UK£122.77m |
| Earnings | -UK£129.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | -32.45% |
| Net Profit Margin | -616.50% |
| Debt/Equity Ratio | 0.1% |
How did EXAI perform over the long term?
See historical performance and comparison